This application proposes to address the problem of elevated cytotoxic antibodies that precludes individuals from being successfully crossmatched for transplantation. The main objective of the study is to lower anti-HLA antibody titers in these highly sensitized patients in order to reduce the waiting time for kidney transplantation and the incidence of severe rejection and graft loss. The study is based on the hypothesis that administration of pooled human intravenous gamma globulin (IVIG) will reduce anti-HLA antibody activity and reduce allosensitization after transplantation. The applicants present data from their laboratory and from others that strongly suggest that IVIG contains idiotypic anti-anti-HLA antibodies which have the capacity to inhibit anti-HLA antibody cytotoxicity in vitro and in vivo, and possibly enhance allograft survival. The applicants propose a double-blinded, randomized controlled clinical trial of IVIG vs placebo in 100 highly HLA sensitized adult patients with End-Stage Renal Disease (ESRD) that are awaiting kidney transplantation. Patients awaiting transplantation will receive three treatments of IVIG or placebo prior to transplantation and three treatments post-transplantation. The trial will determine if IVIG is superior to placebo in: (1) lowering anti-HLA antibody titers and other measures of alloreactivity, (2) reducing waiting time to transplantation, and (3) improving transplant survival.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Research Project--Cooperative Agreements (U01)
Project #
Application #
Study Section
Special Emphasis Panel (ZAI1-KMC-I (20))
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Cedars-Sinai Medical Center
Los Angeles
United States
Zip Code
Toyoda, Mieko; Puliyanda, Dechu P; Amet, Nurmamet et al. (2005) Co-infection of polyomavirus-BK and cytomegalovirus in renal transplant recipients. Transplantation 80:198-205
Toyoda, Mieko; Petrosyan, Anna; Pao, Andy et al. (2004) Immunomodulatory effects of combination of pooled human gammaglobulin and rapamycin on cell proliferation and apoptosis in the mixed lymphocyte reaction. Transplantation 78:1134-8
Jordan, Stanley C; Tyan, Dolly; Stablein, Don et al. (2004) Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: report of the NIH IG02 trial. J Am Soc Nephrol 15:3256-62
Toyoda, Mieko; Pao, Andy; Petrosian, Anna et al. (2003) Pooled human gammaglobulin modulates surface molecule expression and induces apoptosis in human B cells. Am J Transplant 3:156-66
Jordan, S C; Vo, A; Bunnapradist, S et al. (2003) Intravenous immune globulin treatment inhibits crossmatch positivity and allows for successful transplantation of incompatible organs in living-donor and cadaver recipients. Transplantation 76:631-6
Jordan, Stanley C; Vo, Ashley; Bunnapradist, Suphamai et al. (2002) Treatment of active cytomegalovirus disease with oral ganciclovir in renal allograft recipients: monitoring efficacy with quantitative cytomegalovirus polymerase chain reaction. Am J Transplant 2:671-3
Bunnapradist, S; Jordan, S C (2000) The role of cytokines and cytokine gene polymorphism in T-cell activation and allograft rejection. Ann Acad Med Singapore 29:412-6
Toyoda, M; Petrosian, A; Jordan, S C (1999) Immunological characterization of anti-endothelial cell antibodies induced by cytomegalovirus infection. Transplantation 68:1311-8
Jordan, S C; Quartel, A W; Czer, L S et al. (1998) Posttransplant therapy using high-dose human immunoglobulin (intravenous gammaglobulin) to control acute humoral rejection in renal and cardiac allograft recipients and potential mechanism of action. Transplantation 66:800-5